Kuick Research releases a study on the US Orphan Drug Market, offering insights for investors. The market is expected to reach over $190 billion by 2030, with over 850 orphan drugs in clinical trials. Keytruda and Biktarvy are examples of orphan drugs that have become blockbuster successes, highlighting the market’s potential. Collaborations, like Cadrenal Therapeutics and Abbott’s partnership for tecarfarin, are driving innovation. The US orphan drug market continues to grow, attracting diverse capital and benefiting from regulatory changes. The sector presents a unique opportunity for investors seeking both social impact and financial returns.

Read more at GlobeNewswire: Kuick Research Releases Landmark Study On US Orphan Drug